Insights

Strategic partnerships Nurix engages in multiple high-profile collaborations with Roche, Gilead, Pfizer, and Sanofi, indicating strong potential for co-development and licensing conversations. Sales opportunities exist in expanding existing alliances or initiating new deals around degrader-based therapies and target expansion.

Clinical momentum With active Phase 1/2 data and ongoing trials such as bexobrutideg, Nurix demonstrates a translational pipeline and near-term clinical milestones that can drive partnering discussions, sponsored research, and potential in-licensing of later-stage assets.

Financial strength Substantial funding and a revenue range in the tens of millions, supported by a large funding total, position Nurix to pursue strategic collaborations, milestone-driven deals, and capacity expansions without immediate capital constraints.

Degrader leadership Expertise in targeted protein degradation and a diverse pipeline spanning autoimmune, oncology, and immunology spaces create cross-sell opportunities for contract research, development services, and platform licensing to biopharma players seeking degrader capabilities.

Global reach Ongoing multinational collaborations and a broad international signaling (Europe via EHA presentation, global licenses) indicate readiness for cross-border partnerships, regional co-development, and joint ventures to leverage Nurix’s UD degradation platform.

Similar companies to Nurix Therapeutics

Nurix Therapeutics Tech Stack

Nurix Therapeutics uses 8 technology products and services including Apache Spark, OneTrust, PostgreSQL, and more. Explore Nurix Therapeutics's tech stack below.

Media & News

Nurix Therapeutics's Email Address Formats

Nurix Therapeutics uses at least 7 email formats:
Nurix Therapeutics Email FormatsExamplePercentage
FLast@nurixtx.comJDoe@nurixtx.com
73%
Last@nurixtx.comDoe@nurixtx.com
25%
First.Last@nurixtx.comJohn.Doe@nurixtx.com
2%
FLast@nurix-inc.comJDoe@nurix-inc.com
89%
Last@nurix-inc.comDoe@nurix-inc.com
9%
FMiddleLast@nurix-inc.comJMichaelDoe@nurix-inc.com
1%
First@nurix-inc.comJohn@nurix-inc.com
1%

Frequently Asked Questions

What is Nurix Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Nurix Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Nurix Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Nurix Therapeutics is a publicly traded company; the company's stock symbol is NRIX.

What is Nurix Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Nurix Therapeutics's official website is nurixtx.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Nurix Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Nurix Therapeutics's annual revenue is estimated to be $50M - $100M.

What is Nurix Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Nurix Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Nurix Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Nurix Therapeutics has approximately 381 employees across 3 continents, including North America, Asia and Europe. Key team members include Chief Executive Officer: R. K., Chief Medical Officer: P. O. and Vice President Of Cell Therapy And Cancer Immunology: E. W. Explore Nurix Therapeutics's employee directory with LeadIQ.

What industry does Nurix Therapeutics belong to?

Minus sign iconPlus sign icon
Nurix Therapeutics operates in the Biotechnology Research industry.

What technology does Nurix Therapeutics use?

Minus sign iconPlus sign icon
Nurix Therapeutics's tech stack includes Apache Spark, OneTrust, PostgreSQL, NetSuite, ServiceNow, WP Engine, Microsoft Sentinel and Microsoft Teams.

What is Nurix Therapeutics's email format?

Minus sign iconPlus sign icon
Nurix Therapeutics's email format typically follows the pattern of FLast@nurixtx.com. Find more Nurix Therapeutics email formats with LeadIQ.

How much funding has Nurix Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Nurix Therapeutics has raised $796M in funding. The last funding round occurred on Oct 22, 2025 for $250M.

When was Nurix Therapeutics founded?

Minus sign iconPlus sign icon
Nurix Therapeutics was founded in 2012.
Nurix Therapeutics logo

Nurix Therapeutics

Biotechnology ResearchCalifornia, United States201-500 Employees

Nurix Therapeutics is a mid-sized biotechnology company based in Brisbane, California, focused on the discovery, development, and commercialization of targeted protein degradation medicines. The company aims to transform disease treatment by exploiting the cell’s ubiquitin-proteasome system to remove disease-causing proteins, seeking options that address limitations of existing therapies. It describes itself as a clinical-stage biopharmaceutical company, actively advancing degraders through development. This approach places Nurix within the biotechnology research sector, pursuing a methodology that centers on protein degradation.

Its work targets areas including malignant hematology, immunology, and neurology, supported by strategic collaborations such as a global Roche partnership to co-develop and co-commercialise a BTK degrader, bexobrutideg. In 2026, Nurix announced bexobrutideg-related presentations at scientific meetings, reflecting ongoing clinical development.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
NRIX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2012
Employees
201-500

Section iconFunding & Financials

  • $796M

    Nurix Therapeutics has raised a total of $796M of funding over 9 rounds. Their latest funding round was raised on Oct 22, 2025 in the amount of $250M as a Post IPO Equity.

  • $50M - $100M

    Nurix Therapeutics's revenue is estimated to be in the range of $50M - $100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.